4-bromo-6-nitro-1H-benzo[d]imidazole | 206759-50-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-bromo-6-nitro-1H-benzo[d]imidazole
• 英文别名: 7-Bromo-5-nitro-1H-benzimidazole；4-bromo-6-nitro-1H-benzimidazole
• CAS: 206759-50-4
• 化学式: C₇H₄BrN₃O₂
• 分子量: 242.032
• InChiKey: QVLQTTFTEFTUJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-bromo-6-nitro-1H-benzo[d]imidazole 在 四(三苯基膦)钯 、 水 、 铁粉 、 potassium carbonate 、 氯化铵 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 N-(1-benzyl-4-phenyl-1H-benzo[d]imidazol-6-yl)formamide
  参考文献：
  名称：

  BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS

  摘要：

  描述了公式I的新化合物，这些化合物是选择性HDAC6抑制剂，适用于治疗与HDAC6相关的疾病，其中X、Y、Z、A1、A2、Q1和Q2如所述。

  公开号：

  US20220041584A1
• 作为产物：
  描述：

  2-溴-4,6-二硝基苯胺 在 sodiumsulfide nonahydrate 、 氯化铵 、 sulfur 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 0.75h， 生成 4-bromo-6-nitro-1H-benzo[d]imidazole
  参考文献：
  名称：

  Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors

  摘要：

  这项发明涉及苯并咪唑硼酸衍生物用于调节磷脂酰肌醇3′ OH激酶家族（以下简称PI3激酶）的活性或功能，特别是抑制其活性。适当地，PI3Kα、PI3Kδ、PI3Kβ和/或PI3Kγ。适当地，本发明涉及苯并咪唑硼酸在治疗以下一种或多种疾病状态中的应用：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活动力、移植排斥、移植排斥和肺部损伤。更适当地，本发明涉及PI3Kβ选择性苯并咪唑硼酸化合物用于治疗癌症。

  公开号：

  US20130157977A1

文献信息

• Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors
  申请人：GlaxoSmithKline LLC

  公开号：US20130157977A1

  公开（公告）日：2013-06-20

  This invention relates to the use of benzimidazole boronic acid derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazole boronic acids in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazole boronic acid compounds for treating cancer.

  这项发明涉及苯并咪唑硼酸衍生物用于调节磷脂酰肌醇3′ OH激酶家族（以下简称PI3激酶）的活性或功能，特别是抑制其活性。适当地，PI3Kα、PI3Kδ、PI3Kβ和/或PI3Kγ。适当地，本发明涉及苯并咪唑硼酸在治疗以下一种或多种疾病状态中的应用：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活动力、移植排斥、移植排斥和肺部损伤。更适当地，本发明涉及PI3Kβ选择性苯并咪唑硼酸化合物用于治疗癌症。
• Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
  申请人：GlaxoSmithKline LLC

  公开号：US08778937B2

  公开（公告）日：2014-07-15

  This invention relates to the use of benzimidazole boronic acid derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazole boronic acids in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazole boronic acid compounds for treating cancer.

  本发明涉及苯并咪唑硼酸衍生物的使用，用于调节磷脂酰肌醇3'-OH激酶家族（以下简称PI3激酶）的活性或功能，特别是抑制其活性或功能，适宜地，PI3Kα、PI3Kδ、PI3Kβ和/或PI3Kγ。适宜地，本发明涉及苯并咪唑硼酸在治疗以下一种或多种疾病状态的使用：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官衰竭、肾脏疾病、血小板聚集、癌症、精子运动能力、移植排斥、移植物排斥和肺损伤。更适宜地，本发明涉及PI3Kβ选择性苯并咪唑硼酸化合物用于治疗癌症。
• Benzimidazole compounds as HDAC6 inhibitors
  申请人：OnKure, Inc.

  公开号：US11339150B2

  公开（公告）日：2022-05-24

  Novel compounds of Formula I are described, where the compounds are selective HDAC6 inhibitors suitable for treatment of diseases associated with HDAC6, where X, Y, Z, A1, A2, Q1 and Q2 are as described.

  描述了式 I 的新型化合物，其中化合物是适用于治疗与 HDAC6 相关疾病的选择性 HDAC6 抑制剂，其中 X、Y、Z、A1、A2、Q1 和 Q2 如上所述。
• Chemical- and Sediment-Mediated Reduction of the Azo Dye Disperse Blue 79
  作者：Eric J. Weber、Rebecca L. Adams

  DOI：10.1021/es00005a005

  日期：1995.5.1

  Disperse Blue 79, a large volume disperse azo dye, and 2-bromo-4,6-dinitroaniline (BDNA), an important intermediate in the preparation of Disperse Blue 79, were readily reduced chemically and in three anoxic sediment-water systems studied; half-lives were on the order of minutes to hours. No reduction of Disperse Blue 79 or BDNA was observed however in a sediment-water system containing sediment with low organic carbon. The reaction kinetics of Disperse Blue 79 in the reducing Sediments are biphasic, that is, the initial rapid loss of dye is followed by a much slower rate of transformation. The reaction pathways for the chemical and sediment-mediated reduction of Disperse Blue 79 were quite similar, suggesting that the chemical reduction of such complex chemicals can provide valuable insight into their reaction pathways in environmental systems. For Disperse Blue 79, a number of reaction products resulting from the reduction of both the azo linkage and aromatic nitro groups were formed. The sediment-mediated reduction of BDNA was regioselective resulting in the formation of a 3-bromo-5-nitro-1,2-diaminobenzene, which was further reduced at a much slower rate to B-bromo-1,2,4-triaminobenzene. These results suggest that Disperse Blue 79 and BDNA may undergo reduction in some natural anoxic sediments, resulting in the subsequent release of potentially hazardous aromatic amines to the water column.
• US8778937B2
  申请人：——

  公开号：US8778937B2

  公开（公告）日：2014-07-15